These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 16288376

  • 61. Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model.
    Delagrave S, Hernandez H, Zhou C, Hamberger JF, Mundle ST, Catalan J, Baloglu S, Anderson SF, DiNapoli JM, Londoño-Hayes P, Parrington M, Almond J, Kleanthous H.
    PLoS One; 2012; 7(10):e46714. PubMed ID: 23071620
    [Abstract] [Full Text] [Related]

  • 62. Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission?
    Bollen LJ, Whitehead SJ, Mock PA, Leelawiwat W, Asavapiriyanont S, Chalermchockchareonkit A, Vanprapar N, Chotpitayasunondh T, McNicholl JM, Tappero JW, Shaffer N, Chuachoowong R.
    AIDS; 2008 Jun 19; 22(10):1169-76. PubMed ID: 18525263
    [Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64. Herpes simplex virus type 1 envelope subunit vaccine not only protects against lethal virus challenge, but also may restrict latency and virus reactivation.
    Rajcáni J, Sabó A, Mucha V, Kostál M, Compel P.
    Acta Virol; 1995 Feb 19; 39(1):37-49. PubMed ID: 7572468
    [Abstract] [Full Text] [Related]

  • 65. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy.
    Mo A, Musselli C, Chen H, Pappas J, Leclair K, Liu A, Chicz RM, Truneh A, Monks S, Levey DL, Srivastava PK.
    Vaccine; 2011 Nov 03; 29(47):8530-41. PubMed ID: 21767588
    [Abstract] [Full Text] [Related]

  • 66. An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.
    Skoberne M, Cardin R, Lee A, Kazimirova A, Zielinski V, Garvie D, Lundberg A, Larson S, Bravo FJ, Bernstein DI, Flechtner JB, Long D.
    J Virol; 2013 Apr 03; 87(7):3930-42. PubMed ID: 23365421
    [Abstract] [Full Text] [Related]

  • 67. Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus.
    Diaz FM, Knipe DM.
    Virology; 2016 Jan 15; 488():61-7. PubMed ID: 26609935
    [Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69. DNA immunization against experimental genital herpes simplex virus infection.
    Bourne N, Stanberry LR, Bernstein DI, Lew D.
    J Infect Dis; 1996 Apr 15; 173(4):800-7. PubMed ID: 8603957
    [Abstract] [Full Text] [Related]

  • 70. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.
    Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL.
    J Immunol; 2001 Mar 01; 166(5):3451-7. PubMed ID: 11207303
    [Abstract] [Full Text] [Related]

  • 71. Topical SMIP-7.7, a toll-like receptor 7 agonist, protects against genital herpes simplex virus type-2 disease in the guinea pig model of genital herpes.
    Bernstein DI, Cardin RD, Bravo FJ, Earwood J, Clark JR, Li Y, Mishra P, Li C, Nayak BP, Miller AT, Wu TY, Cooke MP, Valiante NM.
    Antivir Chem Chemother; 2014 Apr 11; 23(5):189-96. PubMed ID: 23232327
    [Abstract] [Full Text] [Related]

  • 72. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
    Sperling RS, Fife KH, Warren TJ, Dix LP, Brennan CA.
    Sex Transm Dis; 2008 Mar 11; 35(3):286-90. PubMed ID: 18157071
    [Abstract] [Full Text] [Related]

  • 73. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial.
    Mark KE, Corey L, Meng TC, Magaret AS, Huang ML, Selke S, Slade HB, Tyring SK, Warren T, Sacks SL, Leone P, Bergland VA, Wald A.
    J Infect Dis; 2007 May 01; 195(9):1324-31. PubMed ID: 17397003
    [Abstract] [Full Text] [Related]

  • 74. Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization.
    Cherpes TL, Melan MA, Kant JA, Cosentino LA, Meyn LA, Hillier SL.
    Clin Infect Dis; 2005 May 15; 40(10):1422-8. PubMed ID: 15844064
    [Abstract] [Full Text] [Related]

  • 75. Novel Adjuvant S-540956 Targets Lymph Nodes and Reduces Genital Recurrences and Vaginal Shedding of HSV-2 DNA When Administered with HSV-2 Glycoprotein D as a Therapeutic Vaccine in Guinea Pigs.
    Awasthi S, Onishi M, Lubinski JM, Fowler BT, Naughton AM, Hook LM, Egan KP, Hagiwara M, Shirai S, Sakai A, Nakagawa T, Goto K, Yoshida O, Stephens AJ, Choi G, Cohen GH, Katayama K, Friedman HM.
    Viruses; 2023 May 10; 15(5):. PubMed ID: 37243234
    [Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs.
    Prichard MN, Kaiwar R, Jackman WT, Quenelle DC, Collins DJ, Kern ER, Kemble GM, Spaete RR.
    Vaccine; 2005 Nov 16; 23(46-47):5424-31. PubMed ID: 15950327
    [Abstract] [Full Text] [Related]

  • 79. Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.
    Görander S, Harandi AM, Lindqvist M, Bergström T, Liljeqvist JÅ.
    J Virol; 2012 Jul 16; 86(14):7544-53. PubMed ID: 22553328
    [Abstract] [Full Text] [Related]

  • 80. Distribution of herpes simplex virus types 1 and 2 genomes in human spinal ganglia studied by PCR and in situ hybridization.
    Obara Y, Furuta Y, Takasu T, Suzuki S, Suzuki H, Matsukawa S, Fujioka Y, Takahashi H, Kurata T, Nagashima K.
    J Med Virol; 1997 Jun 16; 52(2):136-42. PubMed ID: 9179758
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.